Results 101 to 110 of about 1,113 (191)

Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndrome

International Medical Case Reports Journal, 2021
João Heitor Marques,1 Ana Carolina Abreu,1 Nisa Silva,1 Angelina Meireles,1,2 Bernardete Pessoa,1,2 João Melo Beirão1,2 1Serviço de Oftalmologia, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Instituto ...
Marques JH, Abreu AC, Silva N, Meireles A, Pessoa B, Melo Beirão J   +5 more
doaj  

Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study

Journal of Ophthalmic Inflammation and Infection
Background Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and/or vitreoretinal surgery, which may spontaneously resolve.
Maria Madeira, Ana Cabugueira, Helena Urbano, Miguel Cordeiro, Marta Guedes   +4 more
doaj   +1 more source

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months [PDF]

Purpose: This study assessed the effectiveness of the 0.19-mg fluocinolone acetonide (FAc) implant by multimodal measurements in patients with non-infectious uveitis (NIU) in a real-world setting in Spain.
Adán Civera, Alfredo, Coelho Borges, Ana Isabel, Hernanz, Inés, Llorenç, Victor, Moll Udina, Aina, Pazos, Marta, Pelegrín, Laura, Sainz de la Maza Serra, María Teresa   +7 more
core   +1 more source

Real-world safety and efficacy of 0.19 mg fluocinolone acetonide intravitreal implant in the management of recurrent non-infectious uveitis [PDF]

, 2022
Christensen, Louise Fischer, Vorum, Henrik   +1 more
core   +3 more sources

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®)

International Medical Case Reports Journal, 2020
Bernardete Pessoa,1,2 João Melo-Beirão,1,2 Angelina Meireles,1,2 Pedro Menéres1,2 1Ophtalmology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Unit for Multidisciplinary Research in Biomedicine ...
Pessoa B, Melo-Beirão J, Meireles A, Menéres P   +3 more
doaj  

Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results. [PDF]

Eye (Lond), 2023
Dobler E, Mohammed BR, Chavan R, Lip PL, Mitra A, Mushtaq B.   +5 more
europepmc   +1 more source

A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series

Clinical Ophthalmology, 2015
Vera K Schmit-Eilenberger Augenklinik Städtisches Klinikum, Karlsruhe, Baden-Württemberg, Germany Background: Iluvien® is a novel, nonbiodegradable, sustained-release drug delivery system (0.2 µg/d fluocinolone acetonide [FAc ...
Schmit-Eilenberger VK
doaj  

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)

International Medical Case Reports Journal, 2019
Jessica D McCluskey, Paul L Kaufman, Kathy Wynne, Gregory LewisDepartment of Ophthalmology, Thomas Eye Group, Atlanta, GA, USAObjective: To assess long-term outcomes for effectiveness, safety, and treatment burden after injection of 0.2 μg/day ...
McCluskey JD, Kaufman PL, Wynne K, Lewis G   +3 more
doaj  

Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME) [PDF]

, 2015

core   +1 more source

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema

International Medical Case Reports Journal, 2018
P Singh,1 A Chedid,1 SK Deuchler,1 T Kohnen,2 M Müller,2 FH Koch1 1Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany; 2Ophthalmology University Eye Hospital, Frankfurt am Main, Germany Purpose: There are little or no ...
Singh P, Chedid A, Deuchler SK, Kohnen T, Müller M, Koch FH   +5 more
doaj